4¿ù 17ÀÏ(±Ý) |
- Á¦ 2ȸÀÇÀå - |
08:30~10:00 Interesting ECG |
ÁÂÀå : ±è¿µÈÆ, ½Åµ¿±¸ |
Panel: ±èÁØ, ±èÁø¹è, ³²±ÃÁØ, ½Å´ëÈñ, ÀÓÈ«ÀÇ, Çö´ë¿ì |
10:30~12:30 Catheter Ablation Technology |
ÁÂÀå : ÃÖÀ±½Ä, Á¶Á¤°ü |
10:30-10:55 |
1. RF Energy Monitoring During Ablation |
¿À¼¼ÀÏ/¼¿ïÀÇ´ë |
10:55-11:20 |
2. New Energy Sources and Catheters for Ablation
|
ÃÖ±âÁØ/¿ï»êÀÇ´ë |
11:20-11:45 |
3. New Approaches to Unusual Targets |
¹ÚÈñ³²/¿¬¼¼ÀÇ´ë |
11:45-12:10 |
4. Image Integration & Catheter Navigation Technology
|
¿À¿ë¼®/°¡Å縯ÀÇ´ë |
12:10-12:30 |
5. Panel Discussion |
Panel: À̸¸¿µ, À̹®Çü |
14:00~16:00 Update in Interventional Cardiology |
ÁÂÀå : ½É¿øÈì, ±è¿µÁ¶ |
14:00-14:20 |
1. Immediate Beta Blockade in STEMI Patients : Is It Really Helpful?
|
±è ¿ø/°æÈñÀÇ´ë |
14:20-14:40 |
2. Immediate Statin in STEMI Patients : Is It Really Helpful?
|
¹ÚÁ¾¼±/¿µ³²ÀÇ´ë |
14:40-15:00 |
3. Contrast-Induced Nephropathy, Prognostic Implication & Prevention; Current Status
|
Á¶»óÈ£/ÇѸ²ÀÇ´ë |
15:00-15:20 |
4. Plavix Resistance, Cause & Clinical Implication: Current Status
|
¼Á¤¿ø/¼¿ïÀÇ´ë |
15:20-15:40 |
5. Recent Clinical Data of 3rd Generation DES
|
¹èÀåÈ£/°Ç¾çÀÇ´ë |
15:40-16:00 |
6. Panel Discussion |
|
Panel: ±è¹«Çö, ±èÁ¾Áø, ±èÈ¿¼ö, ¹Ú¼º¿í, ¼ºÀÎȯ, ¾È¿µ±Ù, ¾ÈÅÂÈÆ, Àå¾ç¼ö |
16:30~18:30 Debate in Interventional Cardiology |
ÁÂÀå : ½ÅÀͱÕ, ±è±Ç¹è |
In certain patients with Stable Angina |
16:30-16:42 |
1. Medical Treatment is Better
|
ÀÌöȯ/¿ï»êÀÇ´ë |
16:42-16:54 |
2. PCI is Better
|
±è¸í°ï/°æÈñÀÇ´ë |
16:54-17:00 |
3. Panel Discussion |
Panel: ¾çÁÖ¿µ, ¿¬ÅÂÁø, ÃÖµ¿ÈÆ |
In Certain Patients with Multi-vessel Disease |
17:00-17:12 |
1. CABG is Better
|
¹èÀåȯ/ÃæºÏÀÇ´ë |
17:12-17:24 |
2. PCI is Better
|
Çö¹Î¼ö/¼øÃµÇâÀÇ´ë |
17:24-17:30 |
3. Panel Discussion |
Panel: ±è¿µ´ë, ½Â±â¹è, Àüµ¿¿î |
In Certain Patients with Left Main Disease |
17:30-17:42 |
1. CABG is Better
|
±è±âºÀ/¼¿ïÀÇ´ë |
17:42-17:54 |
2. PCI is Better
|
È«¸í±â/¿¬¼¼ÀÇ´ë |
17:54-18:00 |
3. Panel Discussion |
Panel: ±èº´±Ø, ³ª½Â¿î, ¹Ú±Ý¼ö |
In Certain Patients with CTO |
18:00-18:12 |
1. Medical is Better
|
±è¿µÇÐ/¿ï»êÀÇ´ë |
18:12-18:24 |
2. Revascularization is Better
|
À̳»Èñ/¼øÃµÇâÀÇ´ë |
18:24-18:30 |
3. Panel Discussion |
Panel: ¹ÚÇå½Ä, ÀÌÀçȯ, Á¤¸íÈ£ |
- Á¦ 4ȸÀÇÀå - |
08:30~10:00 Controversies in Pediatric Heart Disease |
ÁÂÀå : ³ëÁ¤ÀÏ, ÀÌÁÖ¿ø |
08:30-08:50 |
1. Adult Congenital Heart Disease
|
ÇãÁØ/¼º±Õ°üÀÇ´ë |
08:50-09:10 |
2. Screening for Sudden Death in Childhood and Adolescents
|
±è³²¼ö/ÇѾçÀÇ´ë |
09:10-09:30 |
3. Obseity and Heart Disease in Childhood and Adolescents
|
È«¿µ¹Ì/ÀÌÈÀÇ´ë |
09:30-09:50 |
4. Medical Treatment in Myocarditis and Cardiomyopathy
|
±è¿©Çâ/°è¸íÀÇ´ë |
09:50-10:00 |
5. Panel Discussion |
Panel: ¼Û¿µÈ¯, À̵¿¼®, Áø¼±¹Ì |
10:30~12:30 Recent Advance in Fetal Cardiology |
ÁÂÀå : ÀÌÈïÀç, ¼º½ÃÂù |
10:30-10:50 |
1. The Role of the Fetal Cardiologist in Non-cardiac Fetal Conditions
|
À±½Å¿ø/Áß¾ÓÀÇ´ë |
10:50-11:10 |
2. Heart Failure in the Fetus
|
¼Û¹Î¼·/ÀÎÁ¦ÀÇ´ë |
11:10-11:30 |
3. Fetal Cardiovascular Physiology: Characterization by Echocardiography |
Á¤Á¶¿ø/¾ÆÁÖÀÇ´ë |
11:30-11:50 |
4. Current Status of Fetal Surgical Intervention
|
ÀÌÁ¤·Ä/¼¿ïÀÇ´ë |
11:50-12:10 |
5. Organizing a Comprehensive Fetal Cardiology Program
|
¿øÇý¼º/¿ï»êÀÇ´ë |
12:10-12:30 |
6. Panel Discussion |
Panel: °¼öÁ¤, ¹ÚÁ¤ÁØ, Àº¿µ¹Î |
14:00~16:00 Recent Advance in Pediatric CHF |
ÁÂÀå : ¿ÀºÀ¼®, ÀÌ»ó¹ü |
14:00-14:20 |
1. Diagnosis and Classification
|
ÃÖÀ翵/¿¬¼¼ÀÇ´ë |
14:20-14:40 |
2. Medical Management
|
±è¼öÁø/ºÎõ¼¼Á¾º´¿ø |
14:40-15:00 |
3. Electrophysiology Management : Biventricular Pacing and ICD
|
Çö¸íö/°æºÏÀÇ´ë |
15:00-15:20 |
4. Mechanical Circulatory Support
|
±è½ÃÈ£/µ¿¾ÆÀÇ´ë |
15:20-15:40 |
5. Surgical Strategies for the Failing Systemic Ventricle
|
À±ÅÂÁø/¿ï»êÀÇ´ë |
15:40-16:00 |
6. Panel Discussion |
Panel: ¾çÁöÇõ, ¿ìÇâ¿Á, ¹ÝÁöÀº |
16:30-18:30 Advance in Pediatric Cardiac Surgery |
ÁÂÀå : ±è¿ëÁø, À̱¤¼÷ |
16:30-16:50 |
1. Current Strategy for RVOT Reconstruction
|
¹ÚÇѱâ/¿¬¼¼ÀÇ´ë |
16:50-17:10 |
2. Strategy for Improving Neurologic OutcomeAfter Congenital Cardiac Surgery
|
¹ÚÁ¤ÁØ/¿ï»êÀÇ´ë |
17:10-17:30 |
3. Neonatal Repair vs. Staged Repair in Pulmonary Atresia with VSD
|
¾çÁöÇõ/¼º±Õ°üÀÇ´ë |
17:30-17:50 |
4. Arrhythmia Surgery in Single Ventricle
|
±è¿õÇÑ/¼¿ïÀÇ´ë |
17:50-18:10 |
5. Modifications of Fontan Procedure to Reduce Pulmonary Arteriovenous Malformations
|
ÀÓÈ«±¹/ºÎõ¼¼Á¾º´¿ø |
18:10-18:30 |
6. Panel Discussion |
Panel: ¹Ú¿µÈ¯, ¼µ¿¸¸, ¼º½ÃÂù |
4¿ù 18ÀÏ(Åä) |
- Á¦ 1ȸÀÇÀå - |
08:30~10:00 Advance in Interventional Technology and Device 1 |
ÁÂÀå : Á¶½Â¿¬, ¹Ú½ÂÁ¤ |
08:30-08:45 |
1. OCT
|
Á¶Áø¸¸/°æÈñÀÇ´ë |
08:45-09:00 |
2. Cardiac MRI |
ÀÌ »ó/À»ÁöÀÇ´ë |
09:00-09:15 |
3. Myocardial CT Imaging
|
±èÀ±Çö/Àü³²ÀÇ´ë |
09:15-09:30 |
4. IVUS & VH
|
°í¿µ¿±/Á¶¼±ÀÇ´ë |
09:30-09:45 |
5. FFR & CFR
|
À±¸íÈ£/¾ÆÁÖÀÇ´ë |
09:45-10:00 |
6. Panel Discussion |
|
Panel: ±¸º»±Ç, À±Á¤ÇÑ, ÀÌ»óÈÆ, äÁ¦°Ç, ÃÖ¿µÁø, ÃÖÁøÈ£, ʽÂÁ¦, È«¿µÁØ, È«ÅÃÁ¾ |
10:30~12:00 Advance in Interventional Technology and Device 2 |
ÁÂÀå : ¹Ú¿µ¹è, ÀÌ»óÈÆ |
10:30-10:45 |
1. Myocardial Salvage in AMI-Preconditioning, Postconditioning
|
±èµÎÀÏ/ÀÎÁ¦ÀÇ´ë |
10:45-11:00 |
2. PCPS
|
ÇÑÁÖ¿ë/¼º±Õ°üÀÇ´ë |
11:00-11:15 |
3. EVAR (AAA and Aortic Dissection)
|
°í¿µ±¹/¿¬¼¼ÀÇ´ë |
11:15-11:30 |
4. Drug Eluting Balloon |
¹Ú°æ¿ì/¼¿ïÀÇ´ë |
11:30-11:45 |
5. Next Generation DES
|
ÀÌÁØÈñ/ÇѸ²ÀÇ´ë |
11:45-12:00 |
6. Panel Discussion |
|
Panel: ±ÇÇöö, ÀÌ»ó°ï, À̽Âȯ, Á¶¿µ¼®, Á¤¿í¼º, Â÷±¤¼ö, ÃÖ½ÂÇõ, ÇѱԷÏ, Çã½ÂÈ£ |
12:00~12:40 ¼¼ø±Ô ±³¼ö ±â³äƯ° |
ÁÂÀå : ½ÉºÀ¼· |
12:00-12:40 |
Molecular Control of Vascular Development |
Anne Eichmann/College de France, France |
14:00-16:00 Hypertension in Medtabolic Syndrome |
ÁÂÀå : È«¼øÇ¥, ±èöȣ |
14:00-14:20 |
1. Epidemiologic and Physiologic Relevance of Surrogate Markers for CV Events
|
ÃÖ½ÂÇõ/¼º±Õ°üÀÇ´ë |
14:20-14:40 |
2. Inflammation in Hypertension and Metabolic Syndrome
|
±èÀÀÁÖ/°í·ÁÀÇ´ë |
14:40-15:00 |
3. Aging or Insulin Resistance in Hypertension and Metabolic Syndrome
|
±è±¤ÀÏ/¼¿ïÀÇ´ë |
15:00-15:20 |
4. How to Stop the Progression of Metabolic Syndrome to CV Events
|
À̹«¿ë/µ¿±¹ÀÇ´ë |
15:40-16:00 |
5. Panel Discussion |
Panel: °í±¤°ï, ±è¿µ±Ç, ¹Úâ±Ô, ¼º±âö, Â÷ºÀ¼ö |
- Á¦ 2ȸÀÇÀå - |
08:30-10:00 Novel Targets in AF Management |
ÁÂÀå : ±è¼º¼ø, ¿Àµ¿Áø |
08:30-08:50 |
1. Pathophysiology of AF
|
³²±âº´/¿ï»êÀÇ´ë |
08:50-09:10 |
2. Pharmacological Therapy for Substrate Modification
|
°ûÃæÈ¯/°æ»óÀÇ´ë |
09:10-09:30 |
3. New Antithrombotic Drugs
|
À̸í¿ë/´Ü±¹ÀÇ´ë |
09:30-09:50 |
4. New Antiarrhythmic Drugs
|
¹Ú°æ¹Î/ÀÎÁ¦ÀÇ´ë |
09:50-10:00 |
5. Panel Discussion |
Panel: ±è´ë°æ, ±èÁø¼®, Á¤º´Ãµ |
10:30-12:00 Sudden Cardiac Death |
ÁÂÀå : ³ëÅÂÈ£, ÃÖÀμ® |
10:30-10:50 |
1. Noninvasive Assessment of SCD Risk in Patients with Structural Heart Disease
|
½Åµ¿±¸/¿µ³²ÀÇ´ë |
10:50-11:10 |
2. Role of EPS in the Evaluation of High-Risk Patients for SCD
|
Â÷ÅÂÁØ/°í½ÅÀÇ´ë |
11:10-11:30 |
3. Management of Channelopathy Including LQTS and Brugada Syndrome
|
Á¶¿ë±Ù/°æºÏÀÇ´ë |
11:30-11:50 |
4. ICD for Primary Prevention
|
±è³²È£/¿ø±¤ÀÇ´ë |
11:50-12:00 |
5. Panel Discussion |
Panel: ±èÁؼö, ÀÌ¿µ¼ö, Á¤ÁßÈ |
14:00-16:00 CRT |
ÁÂÀå : ±èÀ¯È£, ±èÀ±³â |
14:00-14:20 |
1. Evaluation of Dyssynchrony |
Á¶±¸¿µ/¼¿ïÀÇ´ë |
14:20-14:40 |
2. Role of CT and MRI for CRT Candidates |
ÀÌ»óö/¼º±Õ°üÀÇ´ë |
14:40-15:00 |
3. Predictors of CRT Response
|
¹ÚÇü¿í/Àü³²ÀÇ´ë |
15:00-15:20 |
4. Current & Emerging Indications of CRT
|
À̰漮/ÀüºÏÀÇ´ë |
15:20-15:40 |
5. Technical Aspects of CRT Device Implantation
|
¹Ú»ó¿ø/°í·ÁÀÇ´ë |
15:40-16:00 |
6. Panel Discussion |
Panel: Á¶¿ë±Ù, Ȳ±³½Â |
- Á¦ 3ȸÀÇÀå -
|
08:30~10:00 Evaluation of Atherosclerosis |
ÁÂÀå : ½ÅÇöÈ£, ±èÄ¡Á¤ |
08:30-08:50 |
1. Gene and Atherosclerosis
|
¹ÚÇö¿µ/±¹¸³º¸°Ç¿ø |
08:50-09:10 |
2. Biomarker of Atherosclerosis
|
¿À¼®±Ô/¿ø±¤ÀÇ´ë |
09:10-09:30 |
3. Imaging of Atherosclerosis
|
±è¿ëÁø/¼¿ïÀÇ´ë |
09:30-09:50 |
4. Primary Prevention of Atherosclerosis
|
ÇѱâÈÆ/¿ï»êÀÇ´ë |
09:50-10:00 |
5. Panel Discussion |
Panel: ±èÀ念, ¼È«¼®, ¼ºÁöµ¿, ±è»óÇö, ÇѽÂȯ |
10:30~12:00 New Insigt for PPAR Agonist : Good and Bad Aspect |
ÁÂÀå : ¹ÚÁ¤ÀÇ, ·ù¿Õ¼º |
10:30-10:50 |
1. PPAR¥ã Agonists and Diabetes Control
|
¿ìÁ¤ÅÃ/°æÈñÀÇ´ë |
10:50-11:10 |
2. PPAR¥ã Regulates Insulin Sensitivity and Atherosclerosis |
¹Ú°æ¼ö/¼¿ïÀÇ´ë |
11:10-11:30 |
3. PPAR¥ã Agonists and CV Mortality
|
È«¼øÁØ/°í·ÁÀÇ´ë |
11:30-11:50 |
4. PPAR¥ä Agonist and Vasculogenesis
|
ÇÑÁ¤±Ô/¼¿ïÀÇ´ë |
11:50-12:00 |
5. Panel Discussion |
Panel: À̹®±Ô, ÀÓ¼ö, Â÷ºÀ¼ö, ÇѱâÈÆ, ȲÁø¿ë |
14:00~16:00 Stem Cell Biology Review |
ÁÂÀå : ÀüÀº¼®, ±èÈ¿¼ö |
14:00-14:25 |
1. Induced Pluripotent Stem Cells; Review of Current Status
|
Á¶ÇöÀç/¼¿ïÀÇ´ë |
14:25-14:50 |
2. Vasculogenic Progenitor Cells; Review of Current Status
|
Á¤Çü¹Î/Â÷¹ÙÀÌ¿ÀÅØ |
15:50-15:15 |
3. Hematopoietic Stem Cells ; Review of the Current Status
|
¾öÇö¼®/±¹¸³¾Ï¼¾ÅÍ |
15:15-15:40 |
4. Cardiomyogenic & Adipose Stem Cells ; Review of the Current Status |
¹é»óÈ«/Ä«Å縯ÀÇ´ë |
15:40-16:00 |
5. Panel Discussion |
Panel: °ÇöÀç, ±è°æ¼ö, ¾È¿µ±Ù, ÀÓµµ¼± |
- Á¦ 4ȸÀÇÀå -
|
08:30-10:00 Heart Failure with Preserved Ejection Fraction |
ÁÂÀå : ¿Àº´Èñ, Á¶¸íÂù |
08:30-08:55 |
1. Clinical Implication and Pathophysiology
|
±èµ¿¿î/ÃæºÏÀÇ´ë |
08:55-09:20 |
2. How to Make a Diagnosis
|
¹Ú´ë±Õ/ÇѸ²ÀÇ´ë |
09:20-09:45 |
3. Which Drug is Choice of Treatment
|
±èÇü¼·/°è¸íÀÇ´ë |
09:45-10:00 |
4. Panel Discussion |
Panel: ±èµ¿¼ö, ±è¿µ±Ç, ¹é»óÈ«, Á¤¿íÁø |
10:30-12:00 Heart Failure with Co-Morbidities |
ÁÂÀå : ÀÌ¸í¹¬, À¯±ÔÇü |
10:30-10:50 |
1. Obesity in Heart Failure
|
°¼®¹Î/¿¬¼¼ÀÇ´ë |
10:50-11:10 |
2. Diabetes in Heart Failure
|
ÁÖ½ÂÀç/Á¦ÁÖÀÇ´ë |
11:10-11:30 |
3. Inflammatory Cytokines in Heart Failure
|
ÇѼº¿ì/°Ç±¹ÀÇ´ë |
11:30-11:50 |
4. Nutrition in Heart Failure
|
½Å¹ÎÁ¤/°í·Á´ëÇб³ |
11:50-12:00 |
5. Panel Discussion |
Panel: ±è¸í¾Æ, ¹ÚÀçÇü, ÀüÀº¼®, Á¶¸íÂù, ÃÖµ¿ÁÖ |
14:00~16:00 Multimodality Imaging for the 'Viability' |
ÁÂÀå : ÀÓÅÂȯ, ¼Õ´ë¿ø |
14:00-14:20 |
1. Viability : Clinical Significance |
¹Ú½Â¿ì/¼º±Õ°üÀÇ´ë |
14:20-14:40 |
2. SPECT
|
°¿øÁØ/¿¬¼¼ÀÇ´ë |
14:40-15:00 |
3. CT
|
¹ÚÀº¾Æ/¼¿ïÀÇ´ë |
15:00-15:20 |
4. Echo
|
¼ÛÁ¾¹Î/¿ï»êÀÇ´ë |
15:20-15:40 |
5. MRI
|
Á¤Á¤ÀÓ/°¡Å縯ÀÇ´ë |
15:40-16:00 |
6. Panel Discussion |
Panel: ÀåÇõÀç, ¿ëȯ¼®, ÀÌÁ¾¹Î |
* Satellite Symposium
|
4¿ù 17ÀÏ(±Ý)
|
- Á¦ 1ȸÀÇÀå -
|
GSK - The Latest Vasodilating Beta Blocker : From Hypertension to Heart Failure |
ÁÂÀå : Á¶½Â¿¬, ÀÌ¸í¹¬ |
|
Action Mechanisms of Nebivolol; Nitric Oxide-releasing and Vasodilating
|
±èÈ¿¼ö/¼¿ïÀÇ´ë |
|
Role of Beta Blocker in Elderly Heart Failure
|
ÀüÀº¼®/¼º±Õ°üÀÇ´ë |
- Á¦ 2ȸÀÇÀå -
|
Sanofi-aventis - New Perspectives in the Management of Cardiovascular Diseases |
ÁÂÀå : ¿Àº´Èñ, Àå¾ç¼ö |
|
RAS Blockade on Atrial Fibrillation; A Dream?
|
¹ÚÁ¤¹è/°üµ¿ÀÇ´ë |
|
The Role of Antiplatelet Therapy in the Era of Drug Eluting Stents |
Cindy L. Grines/Beaumont Hospital, USA |
- Á¦ 3ȸÀÇÀå -
|
Áß¿ÜÁ¦¾à - New Concept of Metabolic Syndrome and Beyond with Statin |
ÁÂÀå : ±è´ö°æ, Á¤¸íÈ£ |
|
Chiba Study |
Kohji Shirai/School of Medicine Toho Univ., Japan |
|
±Þ¼º ½É±Ù°æ»öÁõ ȯÀÚ¿¡¼ Statin »ç¿ëÀ¸·Î Àú¹Ðµµ Áö´Ü¹é ÄÝ·¹½ºÅ×·Ñ ¸ñǥġ¿¡ÀÇ µµ´Þ°ú ¿¹ÈÄ¿ÍÀÇ °ü°è
|
È«¿µÁØ/Àü³²ÀÇ´ë |
|
Safety and Efficacy of Statin in Patients with Acute Myocardial Infarction in an Asian Population
|
³ª½Â¿î/°í·ÁÀÇ´ë |
- Á¦ 4ȸÀÇÀå -
|
Çѵ¶¾àǰ - Early Action in Pulmonary Arterial Hypertension |
ÁÂÀå : Á¤³²½Ä, ¼Õ´ë¿ø |
|
Æó°íÇ÷¾ÐÀÇ ºÐ·ù¿Í Áø´Ü ¹× Æò°¡
|
ÀåÇõÀç/¿¬¼¼ÀÇ´ë |
|
The Future of Pulmonary Arterial Hypertension (PAH) Management -Building on the Evidence |
Nazzareno Galie/Univ. of Bolona, Italy |
4¿ù 18ÀÏ(Åä)
|
- Á¦ 1ȸÀÇÀå -
|
Boehringer Ingelheim & GSK- A New Era of Cardio & Vascular Protection Treatment with High Risk Patients |
ÁÂÀå : ±èÀçÇü, ¿Àµ¿ÁÖ |
|
New Evidences in 24hr Blood Pressure Lowering Effect of Telmisartan in Comparative Trials
|
伺ö/°æºÏÀÇ´ë |
|
ONTARGET : Asian Tolerability
|
¼È«¼®/°í·ÁÀÇ´ë |
- Á¦ 2ȸÀÇÀå -
|
Çѱ¹´ÙÀÌÀÌÂî»êÄì/´ë¿õÁ¦¾à - Optimizing Synergistic Effect of CCB/ARB Combination Therapy |
ÁÂÀå : ¹Ú¿µ¹è, Á¤¸íÈ£ |
|
How to Manage Hypertensive Patients Who Fail to Achieve BP Goal?
|
±èÈ¿¼ö/¼¿ïÀÇ´ë |
|
Combined Therapy with CCB and ARB: A New Combination Treatment Option to Better Control Hypertension |
Franz Messerli/St. Lukes-Roosevelt Hospital Center, USA |
- Á¦ 3ȸÀÇÀå -
|
Merck Serono - Cardiovascular Diseases: Where Highly ¥â-1 Selective Blockers Must be Used |
ÁÂÀå : À¯±ÔÇü, ½Â±â¹è |
|
Clinical Benefits of ¥â-blockers in Hypertension & Heart Failure
|
ÃÖµ¿ÁÖ/¼¿ïÀÇ´ë |
|
Proven Benefits of ¥â-blockers in Ischemic Heart Disease
|
ÀÌöȯ/¿ï»êÀÇ´ë |
- Á¦ 4ȸÀÇÀå -
|
Çѱ¹MSD - New Management of Cardiometabolic Disease |
ÁÂÀå : ÀÌ¿ø·Î, ¹ÚÁ¤ÀÇ |
|
A New Paradigm in the Treatment of Type 2 Diabetes
|
¹é»óÈ«/°¡Å縯ÀÇ´ë |
|
Dual Benefits by Lowering 2 Source of Atherogenic Cholesterol
|
±è»óÇö/¼¿ïÀÇ´ë |